ABC | Volume 114, Nº5, Maio 2020

Ponto de Vista Nascimento et al. Anticoagulação em COVID-19 grave Arq Bras Cardiol. 2020; 114(5):829-833 1. Organização Mundial da Saúde. Relatórios de situação da doença coronavírus 2019 (COVID-2019).[Acesso em 29 de abril 2020] Disponível em: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ situation-reports> 2. Brasil.Ministério da Saúde. Boletim Epidemiológico Especial 08 – COE Coronavírus–09deabrilde2020.[Acessoem29deabrilde2020]Disponível em: < https://www.saude.gov.br/images/pdf/2020/April/09/be-covid-08- final-2.pdf >. 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. 4. Liu K, Fang YY, Deng Y, LiuW, Wang MF, Ma JP, et al. Clinical characteristics of novelcoronaviruscasesintertiaryhospitalsinHubeiProvince.ChinMedJ(Engl). 2020 Feb 07, (online ahead of print)10.1097/CM9.0000000000000744. 5. GuanWJ,NiZY,HuY,LiangWH,OuCQ,He JX,etal.ClinicalCharacteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28; NEJM 0a2002032 6. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020Mar 17(online ahead of print). 7. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA. 2020Mar 13 (online ahead of print). 8. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24 (online ahead of print). 9. Organização Mundial da Saúde (OMS). Relatório da Missão Conjunta OMS- ChinasobreaDoençadeCoronavírus2019(COVID-2019).[Acessoem04abr 2020]Disponívelem: http://www.who.int/docs/default-source/coronaviruse/ who-china-joint-mission-on-covid-19-final-report.pdf>. 10. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020May 23 (online ahead of print). 11. KoreaCentersforDiseaseControlandPreservation.(KCDC)Atualizaçõessobre oCOVID-19naCoréia.[Acessoem04abr2020]Disponívelem:<https://www. cdc.go.kr/board/board.es?mid=a30402000000&bid=0030> 12. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia inWuhan, China: a single- centered,retrospective,observationalstudy.LancetRespirMed.2020.https:// doi.org/10.10116/S2213-2600( 20) 30079-5 13. Estimativaspreliminaresdaprevalênciadedoençassubjacentesselecionadas em pacientes com doença de coronavírus 2019. E.U.A. [Acesso em 04 abr 2020] Disponível em: <https://www.cdc.gov/mmwr/volumes/69/wr/ mm6913e2.htm>. 14. WangD, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 07 (online ahead of print]. 15. ChenT,WuD,ChenH,YanW,YangD,ChenG,etal.Clinicalcharacteristicsof 113deceasedpatientswithcoronavirusdisease2019:retrospectivestudy.BMJ. 2020;368:m1295. Epub 2020Mar 26. 16. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Mar 19;2204326. Referências Figura 2 – O diagnóstico de COVID-19 deve ser confirmado conforme as recomendações da Organização Mundial de Saúde. 37 Pacientes com critérios de gravidade 8,38 em associação com escore de coagulopatia induzida pela sepse ≥ 4 ou coagulação intravascular disseminada e/ou valores de dímero-D > 6 vezes o limite superior da normalidade podem se beneficiar da terapia anticoagulante. RNI: razão de normatização internacional; SIC: coagulopatia induzida pela sepse; ISTH: International Society on Thrombosis and Hemostasis; SOFA: sequential organ failure assessment; CIVD: coagulação intravascular disseminada; LSN: limite superior da normalidade. 832